Epidemic

Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine

Retrieved on: 
fredag, maj 31, 2024
Partnership, Aedes, Health care, Licensure, ANVISA, Marketing, Coalition, CHMP, Food, European Medicines Agency, VLA, FDA, Ageing, Disease, Iberian languages, Climate change, Vaccine, IRP, Fever Dream, Instituto Butantan, European Commission, EMA, Epidemic, Vaccination, MHRA, CEPI, MAA, Health Canada, Committee, Virus, European, Euronext Paris, Brazilian Health Regulatory Agency

If approved, it will become the first chikungunya vaccine available in Europe to address this unmet medical need.

Key Points: 
  • If approved, it will become the first chikungunya vaccine available in Europe to address this unmet medical need.
  • In accordance with the International Recognition Procedure (IRP)1, Valneva is also preparing a Marketing Authorization Application (MAA) for submission to the UK Medicines and Healthcare products Regulatory Agency (MHRA).
  • The CHMP opinion follows the November 2023 approval of IXCHIQ® by the US Food and Drug Administration (FDA)2.
  • Juan Carlos Jaramillo, M.D., Chief Medical Officer of Valneva, commented, “This positive CHMP opinion marks a crucial milestone toward introducing a preventative solution against chikungunya in the EU.

BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem

Retrieved on: 
onsdag, maj 29, 2024
Partnership, Disease, Infection, COVID-19, Republic, Coalition, HIV, Mpox, Messenger, Ecosystem, Developing country, Malaria, Epidemic, Vaccine, Research, Global health, Tuberculosis, CEPI, BNTX, Pandemic, G7, G20

CEPI is committing up to US $145 million1 to support BioNTech to establish mRNA vaccine R&D, clinical and commercial-scale manufacturing capabilities at the Company’s facility in Kigali, Rwanda.

Key Points: 
  • CEPI is committing up to US $145 million1 to support BioNTech to establish mRNA vaccine R&D, clinical and commercial-scale manufacturing capabilities at the Company’s facility in Kigali, Rwanda.
  • This effort by BioNTech and CEPI has the potential to enable R&D activities for novel mRNA-based vaccine candidates against pathogens with epidemic or pandemic potential.
  • Our partnership with CEPI is an important next step in our comprehensive strategy towards sustainable mRNA vaccine manufacturing in Africa.
  • The power of partnership is what will make this project successful, and today is another great milestone towards creating vaccine equity.”
    H.E.

Chevron Updates Stockholders at Annual Meeting

Retrieved on: 
onsdag, maj 29, 2024
Oil, Gas, Energy, Permian, News, Risk, Chevron Corporation, Weather, CVX, Hydrogen, Legislation, Petroleum, Accident, Climate change, Gulf of Mexico, Service, Organization, ACES, Corporation, Hess Corporation, Epidemic, Marketing, Carbon, Annual report, Pandemic, Failure, Professional corporation, Tax, ROCE, Government, Lubricant, Acquisition, Natural gas, Annual general meeting

Chevron Corporation (NYSE: CVX) today provided an overview of the company’s business performance and plans at its 2024 Annual Meeting of Stockholders.

Key Points: 
  • Chevron Corporation (NYSE: CVX) today provided an overview of the company’s business performance and plans at its 2024 Annual Meeting of Stockholders.
  • “Chevron continues to deliver strong operational performance, maintain cost and capital discipline and consistently return cash to shareholders,” said Michael Wirth, Chevron’s chairman and CEO.
  • “Our financial priorities remain unchanged – grow the dividend, invest capital efficiently, maintain a strong balance sheet and return excess cash to stockholders,” Wirth said.
  • Specific information about the proposals before Chevron stockholders this year may be found in the “Investors” section of the company’s website under “Stockholder Services – Annual Meeting Materials.”
    Chevron is one of the world’s leading integrated energy companies.

Insight Enterprises, Inc. Announces Pricing of $500 Million Offering of Senior Notes

Retrieved on: 
onsdag, maj 15, 2024
Security, Data Management, Technology, Artificial Intelligence, Software, Security (finance), NSIT, ABL, Intelligence, Risk, Form 10-K, Sale, Epidemic, Person, Marketing, Form, Regulation, Human, Name, Pandemic, Enterprise, Insight Enterprises, Failure

Insight Enterprises, Inc. (NASDAQ: NSIT) (the “Company”) announced today that it has priced $500 million aggregate principal amount of 6.625% senior notes due 2032 (the “notes”).

Key Points: 
  • Insight Enterprises, Inc. (NASDAQ: NSIT) (the “Company”) announced today that it has priced $500 million aggregate principal amount of 6.625% senior notes due 2032 (the “notes”).
  • The sale of the notes is expected to close on May 20, 2024, subject to customary closing conditions.
  • Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

Barnes & Noble Education Announces Effectiveness of Registration Statement Relating to $45 Million Rights Offering for Common Stock and Commencement of Rights Offering

Retrieved on: 
onsdag, maj 15, 2024
Retail, Other Technology, Convenience Store, Software, Finance, Internet, Online Retail, Professional Services, Technology, Publishing, Other Retail, Other Education, Communications, Continuing, University, Primary, Secondary, Specialty, Training, Education, VitalSource, Special, Risk, Form, BNC, Intelligence, Eastern Time Zone, Sale, Common, Bank, Form S-1, Communication, Immersion Corporation, Virus, Family, Hacking, Security (finance), COVID-19, Epidemic, Marketing, Broker, Computershare, Student, Annual report, Environment, Pandemic, Faculty, Immersion, Rights, Record, Exercise, Textbook, Person, Prospectus, Common stock, Advertising, Date, FC Volna Pinsk

Through the Rights Offering, BNED will issue 900,000,000 shares of its common stock, par value $0.01 per share (the “Common Stock”) at a cash subscription price (the “Subscription Price”) of $0.05 per share.

Key Points: 
  • Through the Rights Offering, BNED will issue 900,000,000 shares of its common stock, par value $0.01 per share (the “Common Stock”) at a cash subscription price (the “Subscription Price”) of $0.05 per share.
  • The Company will not issue fractional shares in the Rights Offering or cash in lieu of fractional shares of Common Stock.
  • Subscription Rights that are not exercised by the expiration date of the Rights Offering will expire and will have no value.
  • If the issuance and sale of our Common Stock pursuant to the Rights Offering is not approved at the Special Meeting, then the Rights Offering will be cancelled.

Insight Enterprises, Inc. Announces Proposed $500 Million Offering of Senior Notes

Retrieved on: 
onsdag, maj 15, 2024
Software, Networks, Internet, Data Management, Technology, Apps, Applications, Mobile, Wireless, Security, Security (finance), NSIT, ABL, Intelligence, Risk, Form 10-K, Sale, Epidemic, Person, Marketing, Form, Senior, Regulation, Human, Name, Note, Pandemic, Enterprise, Insight Enterprises, Failure

Insight Enterprises, Inc. (NASDAQ: NSIT) (the “Company”) announced today that it intends to offer, subject to market and other conditions, $500 million aggregate principal amount of Senior Notes due 2032 (the “notes”).

Key Points: 
  • Insight Enterprises, Inc. (NASDAQ: NSIT) (the “Company”) announced today that it intends to offer, subject to market and other conditions, $500 million aggregate principal amount of Senior Notes due 2032 (the “notes”).
  • Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
  • Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
  • The Company assumes no obligation to update, and, except as may be required by law, does not intend to update, any forward-looking statements.

Insight Enterprises, Inc. Announces Investor Meetings for Potential Offering of Senior Notes

Retrieved on: 
måndag, maj 13, 2024
Data Management, Security, Technology, Software, Networks, Artificial Intelligence, Internet, Offering, NSIT, Security (finance), Intelligence, Risk, Form 10-K, Epidemic, Marketing, Form, Human, Name, Pandemic, Enterprise, Insight Enterprises, Failure

There can be no assurance that the Company will proceed with the Offering at all or, if the Company elects to proceed with the Offering, the terms thereof.

Key Points: 
  • There can be no assurance that the Company will proceed with the Offering at all or, if the Company elects to proceed with the Offering, the terms thereof.
  • This press release is for informational purposes only and is neither an offer to sell nor a solicitation of an offer to buy any security.
  • Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.
  • The Company assumes no obligation to update, and, except as may be required by law, does not intend to update, any forward-looking statements.

Quebecor announces redemption of 4.0% convertible debentures due 2024

Retrieved on: 
måndag, maj 13, 2024
Telecommunications, Toronto Stock Exchange, Judgement, Analysis, Investment, Groupe TVA, Exercise, Government, Epidemic, MVNO, Face, Debenture, Acquisition, Advertising, Pandemic, Public expenditure, TSX, Vidéotron, Security (finance)

MONTRÉAL, May 13, 2024 /CNW/ - Quebecor Inc. ("Quebecor") (TSX: QBR.A),(TSX : QBR.B) today announced that it has issued a redemption notice to holders of its currently outstanding 4.0% convertible unsecured subordinated debentures due June 26, 2024 (the "Debentures").

Key Points: 
  • MONTRÉAL, May 13, 2024 /CNW/ - Quebecor Inc. ("Quebecor") (TSX: QBR.A),(TSX : QBR.B) today announced that it has issued a redemption notice to holders of its currently outstanding 4.0% convertible unsecured subordinated debentures due June 26, 2024 (the "Debentures").
  • As set out in the redemption notice, Quebecor intends to redeem all of the issued and outstanding Debentures on June 25, 2024 (the "Redemption Date").
  • Pursuant to the terms of the Debentures, Quebecor has elected to exercise its Share Redemption Payment Right with respect to the entire outstanding principal amount of the Debentures.
  • Consequently, Quebecor will issue and deliver to the holders, on the Redemption Date, Class B Subordinate Voting Shares ("Class B shares") in accordance with the conversion terms of the Debentures.

Navitas Semiconductor Announces First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 9, 2024
Silicon carbide, CIVI, Probability, Gallium nitride, Risk, Silicon, Epidemic, OBC, Conference, Research, Inspur, Original equipment manufacturer, ICS, Baidu, Form, COVID-19, Form 10-K, Failure, Azure, ThinkBook, Bank statement, Annual report, File, AWS, GAAP, Growth, Video game

TORRANCE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS), the industry leader in next-generation power semiconductors, today announced unaudited financial results for the first quarter ended March 31, 2024.

Key Points: 
  • TORRANCE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Navitas Semiconductor (Nasdaq: NVTS), the industry leader in next-generation power semiconductors, today announced unaudited financial results for the first quarter ended March 31, 2024.
  • On a non-GAAP basis, loss from operations for the quarter was $11.8 million compared to a loss of $12.3 million for the first quarter of 2023.
  • Navitas Q1 2024 Financial Results Conference Call and Webcast Information:
    Toll Free Dial-in: (800) 715-9871 or (646) 307-1963, Conference ID: 4587273
    Our quarterly report on Form 10-Q for the period ended March 31, 2024 is due to be filed with the SEC on May 10, 2024.
  • Each of these non-GAAP financial measures are adjusted from GAAP results to exclude certain expenses which are outlined in the “Reconciliation of GAAP Results to Non-GAAP Financial Measures” tables below.

Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Retrieved on: 
tisdag, maj 7, 2024
FDA, VLA, Bank statement, Fast Track, Research, CHMP, Trial of the century, Biologics license application, Coalition, Profit & Loss, OrbiMed, Lyme disease, Bavarian Nordic, CDC, Notifiable disease, Adolescence, Income tax, Chikungunya, Third party, ACIP, BLA, Licensure, CEPI, PRV, Safety, Travel, Indoor Living, EMA, Marketing, USD, Sale, Tropical disease, EDT, Depreciation, MAA, Profit, Euronext Paris, Zika virus, Epidemic, Adjustment, COGS, Saint-Herblain, COVID-19, Growth, Ageing

Saint-Herblain (France), May 7, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.

Key Points: 
  • Saint-Herblain (France), May 7, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.
  • The condensed consolidated interim financial results are available on the Company’s website ( Financial Reports – Valneva ).
  • In the first quarter of 2024, IXIARO®/JESPECT® sales were €16.6 million compared to €17.4 million in the first quarter of 2023.
  • IXIARO®/JESPECT® sales were €16.6 million in the first quarter of 2024 compared to €17.4 million in the first quarter of 2023.